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Abstract  
Knowledge about placebo mechanisms in patients with chronic pain is scarce. Fibromyalgia 
syndrome (FM) is associated with dysfunctions of central pain inhibition, and since placebo 
analgesia entails activation of endogenous pain inhibition, we hypothesized that long-term 
exposure to FM pain would negatively affect placebo responses. Here we examined the 
placebo-group (n=37, mean age 45 years) from a 12-week, randomized, double-blind, 
placebo-controlled trial investigating the effects of milnacipran or placebo. 22 patients were 
classified as placebo non-responders and 15 as responders, according to the Patient Global 
Impression of Change (PGIC) scale. Primary outcome was the change in pressure pain 
sensitivity from baseline to post-treatment. Secondary outcomes included ratings of clinical 
pain (VAS), FM impact (FIQ) and pain drawing. Among placebo responders, longer FM 
duration was associated with smaller reductions in pressure pain sensitivity (r=0.689, p=.004), 
but not among non-responders (r=-0.348, p=.112). Here, we demonstrate that FM duration 
influences endogenous pain regulation, as pain levels and placebo-induced analgesia were 
negatively affected. Our results point to the importance of early FM interventions, as 
endogenous pain regulation may still be harnessed at that early time. Also, placebo-controlled 
trials should take FM duration into consideration when interpreting results. Clinical trial 
registration EudraCT 2004-004249-16. 
 
Perspective: This article presents a novel perspective on placebo analgesia, as placebo 
responses among patients with chronic pain were analyzed. Long-term exposure to 
fibromyalgia pain was associated with lower placebo analgesia, and the results demonstrate 
the importance of taking pain duration into account when interpreting the results from 
placebo-controlled trials.  
Keywords: placebo analgesia; fibromyalgia; long-term pain; chronic pain; pain inhibition 
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Introduction 
    The ability to endure painful conditions depends largely on activation of endogenous pain 
inhibitory mechanisms in the central nervous system. Pain inhibition is therefore part of the 
normal pain response and modulates the relationship between incoming nociceptive signals 
and perceived pain. In common pain disorders, such as chronic low back pain and 
fibromyalgia syndrome (FM), there is evidence for augmented cerebral processing of pain 2, 15, 
20
. In addition, FM pain has repeatedly been associated with impaired pain inhibition 25, 30, 32 
and decreased activity within pain inhibitory pathways in the brain 20, 21. The inability to 
 c i   e endogenous p in inhibi ion is o  en  e e  ed  o  s ‘disinhibi ion’  nd is   h ll   k o  
FM pathophysiology 20, 30. 
     Placebo analgesia is a term that describes pain reduction in response to an inert treatment 
that mimics a genuine analgesic treatment (e.g. sugar pill) by creating treatment expectations 
of relief. The neurobiological mechanisms of placebo analgesia were first described by Levine 
et al. 34 and since then a large literature has verified the original findings by showing 
activation of cerebral pain inhibitory pathways during placebo analgesia 37, 44 and endogenous 
release of opioids in the brain 48. 
    Since placebo analgesia depends on activation of endogenous pain relief, and FM patients 
are characterized by dysfunctional pain inhibition, the presence of placebo responses among 
FM patients may seem paradoxical. In a recent meta-analysis, where placebo responses in 
drug trials for FM and patients with peripheral diabetic neuropathy were compared, FM 
patients had relatively lower placebo responses than patients with neuropathy 17. The authors 
speculate that the difference may reflect the underlying inability to recruit endogenous 
analgesia among FM patients, compared to patients with neuropathy who are not 
characterized by central disinhibition 17. Yet, there was presence of some degree of placebo 
responses among FM patients 17, 18, and as there was considerable variance in responses 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
 
 
 
 
4 
 
between patients, it is possible that the ability to recruit endogenous pain inhibition varies as a 
function of pain chronification. Several studies have demonstrated brain alterations in 
response to FM pain over time 23, 31, indicating a negative effect of long-term exposure to pain 
that is not attributable to normal aging. In our previous study, we found less grey matter 
volumes and less functional connectivity in the rostral anterior cingulate cortex (rACC) in 
patients with FM 23; a key region for endogenous pain inhibition which is often activated 
during placebo analgesia 5, 10, 37. Hence, it is possible that patients with FM display diminished 
placebo analgesia responses over time as a result of more severe effects on key regions for 
pain inhibition. 
    Here, we investigate the placebo response in FM patients in relation to time since onset of 
widespread pain. In line with the evidence for dysfunctional endogenous pain regulation in 
FM, and more pronounced brain alterations over time, we hypothesized that patients with long 
exposure to FM symptoms would have lower placebo responses. In order to address this 
question, we used the placebo data from a double-blind, randomized, placebo-controlled 
clinical trial where patients were treated with the selective Noradrenalin Serotonin Re-uptake 
Inhibitor (SNRI) milnacipran, or placebo. 
 
Methods  
Patients  
A total of 92 patients were randomized and included in the overall clinical trial, whereof 46 
were randomized to the placebo arm. Outcome data from 38 patients in the placebo group was 
available after treatment, yet one patient was excluded from the statistical analyses due to en 
passant neurological findings. Hence, all statistics are based on 37 patients. Results from the 
overall clinical trial can be found in previous publications.22,38. Patients eligible for 
inclusion were females, aged 18–55 years, fulfilling the ACR 1990 criteria for FM 47 and with 
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a self reported average weekly pain intensity of at least 40 mm on a 100 mm visual analogue 
sc le (VAS),   nging   o  “no p in”  nd “wo s  i  gin ble p in”. Exclusion criteria 
included: presence of severe psychiatric illness, significant risk of suicide, a history of 
substance-, drug- or alcohol abuse, significant cardiovascular/pulmonary disease (including 
ECG abnormalities and hypertension), liver disease, renal impairment, pregnancy or 
breastfeeding. Therapies that could interfere with the tested treatment were prohibited; i.e., 
antidepressants and mood stabilizers, analgesics (tramadol, codeine, dextropropoxyphene), 
strong opioids including patches, anesthetic transdermal patches, anticonvulsants, centrally 
acting relaxants, joint injections, trigger/tender point injections, biofeedback and 
Transcutaneous Electrical Nerve Stimulation (TENS). Paracetamol and dipyrone were 
allowed as rescue medicines and short-term use of zolpidem was allowed as treatment for 
insomnia. Nonsteroidal anti-inflammatory drugs (NSAIDs) were allowed under control from 
the study investigators. Rescue medications and NSAIDs had to be discontinued 48 hours 
prior to assessments of symptoms and pain sensitivity. This study was approved by the local 
ethical committee at each site, and informed consent was obtained before inclusion. Initial 
information about the study was given to patients over the phone, and then again during a 
meeting where the patient received written and oral information. Patients were informed that 
the study was aimed at assessing the effect of milnacipran on sensitivity to pressure and 
cerebral processing of pain. Milnacipran was described as an antidepressant with previously 
demonstrated positive effects on FM symptoms, exemplified by decreased pain, improved 
mood, quality of life and physical function. Initial information about the study was given to 
patients over the phone, and then again during a meeting where the patient received written 
and oral information. Patients were informed that the study was aimed at assessing the effect 
of milnacipran on sensitivity to pressure and cerebral processing of pain. Milnacipran was 
described as an antidepressant with previously demonstrated positive effects on FM 
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symptoms, exemplified by decreased pain, improved mood, quality of life and physical 
function. Furthermore, patients were informed that the study was double blind and that each 
patient had a 50/50 likelihood of receiving milnacipran or placebo. Patients were informed 
that a common side-effect of milnacipran treatment is nausea, and could also read about rare 
side-effects in the written information. Allocation of the medication was performed by study 
staff upon each study visit, by giving the patient a new box with pills. 
 
Procedure 
This study was a randomized, double-blind, placebo-controlled, parallel-group trial assessing 
the effects of 12 weeks treatment with milnacipran or placebo (EudraCT no. 2004-004249-
16). Patients were mainly recruited from primary care at the different study sites; London 
(England), Cologne (Germany) and Stockholm (Sweden). A screening visit was scheduled 7-
28 days prior to study inclusion and consisted of a clinical examination, questionnaires and 
laboratory tests in order to confirm eligibility. A second visit (baseline visit) was scheduled 
following at least 7 days, or the time needed for medication wash-out. During the second visit, 
baseline assessments were performed. The following day, patients returned for a brain scan 
and then started the treatment (milnacipran/placebo). Following a three weeks dose escalation, 
patients had a nine-week fixed dose phase of milnacipran or placebo. Two follow-up visits 
were scheduled between baseline and study end, including checks of compliance, adverse 
events, pain ratings and vital signs. Patients returned in week 12 (day 83 ± 1 day) for the 
evaluation of treatment effects followed by a 9-day down-titration phase. 
 
Responder classification 
After treatment (week 12), patients rated their subjective impression of treatment effect, using 
the Patient Global Impression of Change (PGIC) questionnaire 19, 39 with the options: very 
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much improved (1), much improved (2), minimally improved (3), no change (4), minimally 
worse (5), much worse (6) and very much worse (7). Treatment responders were a priori 
defined as patients reporting any type of improvement (i.e. PGIC 1, 2 or 3). Non-responders 
were defined as patients having no change (i.e. PGIC 4) or worsening of symptoms (i.e. PGIC 
5, 6 o  7). P IC is   co  onl  used sc le e su ing  he p  ien s’ subjec i e  epo   o  clinic l 
improvement in relation to a given treatment.  
 
Baseline characteristics 
In order to characterize patients at baseline, they rated the duration of their widespread pain 
(FM duration, months),  s well  s  he deg ee o  dep essi e s  p o s (Beck’s Dep ession 
Inventory, BDI) 3, anxiety (Spielberger State Trait Anxiety Inventory, STAI-T) 42, 
catastrophizing thoughts (subscale of the Coping Strategies Questionnaire, CSQ) 8 and 
general health (complete SF-36, combination of mental and physical component) 45. 
 
Primary outcome – pressure pain sensitivity (P50) 
The p i     ou co e o   his   i l w s p  ien s’ ch nge in p essu e p in sensitivity from 
baseline to post treatment (value calculated as [post treatment pressure (kPa) – baseline 
pressure (kPa)]). Pressure stimulations were applied to the left thumbnail using an automated, 
pneumatic, computer-controlled stimulator with a plastic piston that applies pressure via a 
1cm2 probe 20. Patients were assessed for pressure pain sensitivity by receiving one ascending 
series of pressure stimuli and one randomized series. Pain intensity in response to each 
s i ulus w s    ed on   100    Visu l An logue Sc le (VAS),  ncho ed wi h “no p in”  nd 
“wo s  i  gin ble p in”. A pol no i l  eg ession  unc ion w s used  o de e  ine e ch 
indi idu l’s  ep esen   ion o  VAS 50   , b sed on 15   ndo ized s i uli in  he   nge 
be ween e ch p  ien ’s p in  h eshold  nd  he  i s  p essu e  h   exceeded VAS 60 mm. The 
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polynomial regression was used because the relationship between stimulus (pressure) and 
response (pain ratings) had non-linear properties. The exact amount of pressure required to 
e oke e ch indi idu l’s p in    VAS 50   is  e e  ed  o  s P50. 
 
Secondary outcome measures  
Secondary outcome measures were collected before and after treatment and included: FM 
p in    i bili   c lcul  ed  s e ch p  ien ’s di  e ence be ween weekl   ini u   nd weekl  
maximum pain intensities (max-min) (VAS 0-100 mm) at baseline; average weekly pain 
intensity (VAS); number of painful areas (pain drawing); impact of FM symptoms 
(Fibromyalgia Impact Questionnaire, FIQ) 7. 
 
Statistical analyses 
Differences at baseline, and differences from baseline to after treatment, were analyzed using 
one sample t-tests (within groups) and independent samples t-tests (between groups). Due to 
the nonparametric properties of VAS ratings, the pain ratings (average weekly pain, pain 
variability) and P50 were analyzed with Wilcoxon signed-rank tests (within groups) and 
Mann-Whitney U tests (between groups). Correlation analyses were performed using 
Spe    n’s r coefficient (when ordinal measures were included), except for the correlation 
between FM duration and age, which was analyzed with Pearson’s r (continuous measures). 
All statistical analyses were performed in SPSS 23.0. The significance level was set as p < 
0.05, two-tailed.  
 
Results 
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Patient characteristics  
Among all patients in the placebo arm of this clinical trial, 22 patients were non-responders 
and 15 were responders according to the PGIC measure. The mean age across responders and 
non-responders was 45 years, and patients had suffered from widespread pain for an average 
of 132 months (11 years) (Table 1). 
 
Baseline comparisons between placebo responders and non-responders  
Placebo responders had lower ratings of depression (BDI) at baseline compared to non-
responders (p=0.015), and less catastrophizing thoughts (CSQ) (p=0.021). No significant 
differences were found in any other baseline variables between the groups (Table 1). 
== Table 1 == 
 
Change from baseline to after treatment for placebo responders and non-responders 
Patients who reported a positive treatment response on PGIC were significantly improved in 
almost all outcomes measures from before treatment to after treatment, including FM impact 
(FIQ; p=0.001), average weekly pain intensity (VAS; p=0.001) and pain drawing (p=0.003), 
but not for P50 (p=0.865). Conversely, placebo non-responders did not improve in any 
outcomes; FM impact (p=0.160), average weekly pain intensity (p=0.495), pain drawing 
(p=0.780) or P50 (p=0.485) (Table 2). This provided validation that the general PGIC 
categorization of responders and non-responders was consistently reflected in our pain-
specific outcome measures. 
== Table 2 == 
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The effect of FM duration on P50 - Baseline 
A correlation analysis between age and FM duration revealed that the two variables were 
independent, both in the placebo responder group, r(13)=0.331, p=0.228, and the placebo 
non-responder group, r(20)=0.299, p=0.176. This means that long FM durations were not 
only present in older patients, and short durations not only present in the younger, and our 
subsequent analyses of FM duration would thus not be confounded by age.  
     Among non-responders there was a negative correlation between FM duration and baseline 
P50, r(20)=-0.496, p=0.019, but not among responders r(13)=-0.318, p=0.248) (see Figure 1). 
Across groups, there was no baseline correlation between FM duration and P50, r(35)=-0.178, 
p=0.292. 
== Figure 1 == 
 
The effect of FM duration on P50 change from baseline to after treatment 
Across groups, there was no significant correlation between FM duration and the primary 
outcome measure, defined as the mean change in P50 from baseline to after treatment, 
r(35)=0.040, p=0.816. Yet, there was a significant negative correlation between FM duration 
and mean change in P50 among placebo responders r(13)=-.689, p=0.004, indicating that 
longer FM duration was associated with lower placebo-induced reductions in pain sensitivity. 
There was no significant association between FM duration and treatment responses among 
non-responders r(20)=.348, p=0.112, (Figure 2). In order to control for the possible influence 
of depression (BDI) and catastrophizing (CSQ) scores on the results, we performed partial 
correlations between FM duration and P50, controlling for BDI and CSQ. Using partial 
correlations, we found the same results, i.e. there was a significant correlation between FM 
duration and mean change in P50 among placebo responders r(13)=0.603, p=0.029, but not 
among non-responders r(20)=-0.376, p=0.102. 
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== Figure 2 == 
 
The relationship between FM duration and pain symptom variability  
The    i bili   o  p  ien s’ weekl  p in s  p o s did no  di  e  be ween g oups    b seline 
(p=.143) (Table 1). There was an overall correlation between pain variability and FM 
duration, indicating that variability in pain symptoms decrease over time in favor of more 
constant weekly pain levels, r(35)=-0.345, p=0.037. In separate correlations for placebo 
responders and non-responders, this negative correlation was seen among non-responders 
r(20)=-0.480, p=0.024, but not among placebo responders r(13)=-0.070, p=0.805 (Figure 3). 
 
== Figure 3 == 
 
Discussion 
 
Here we demonstrate that placebo responses among FM patients in our study were affected by 
the duration of chronic widespread pain. In line with previous evidence for neural plasticity in 
response to chronic pain exposure 1, 31, 35, 36, 40, we found that the response to placebo 
treatment was reduced as a function of FM duration. Pain relief in response to placebo 
treatment has been widely investigated in healthy individuals, and involves activation of pain 
inhibitory circuitry in the brain and endogenous release of opioids 10, 43. Since FM is 
ch   c e ized b  i p i ed  unc ion o   he b  in’s p in inhibi o   s s e , pl cebo  n lgesi  
may seem paradoxical. Yet, two comprehensive meta-analyses of placebo responses in FM 
clinical trials 17, 18 confirm the presence of placebo responses in FM, even if responses were 
lower in FM compared to patients with peripheral neuropathy 17. 
     The mechanisms responsible for placebo analgesia in FM are not well understood. In 
healthy subjects, brain areas rich in opioid receptors, such as the rostral anterior cingulate 
cortex (rACC) have been implicated in placebo analgesia 37. Compared to healthy subjects, 
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reduced pain related activation of rACC 20 and lower functional connectivity between the 
rACC and other parts of the pain inhibitory network 21 have been documented in FM patients. 
FM patients also had reduced rACC volumes in relation to the duration of FM 23. 
Furthermore, FM patients had lower my opioid receptor binding potential (MOR BP) 
compared to healthy controls in brain areas implicated in pain inhibitory networks and 
placebo analgesia, including rACC 16. Recently, Scherpf et al. 41 observed strong within-FM 
patients associations between MOR BP and cerebral pain related activations in rACC, PCC 
and medial frontal gyrus, which were related to pain intensity, i.e., lower MOR BP were 
associated with weaker pain related brain activations and higher pain ratings. In our previous 
study, specifically comparing milnacipran with placebo responders, we found segregated 
neural mechanisms for the positive response in FM patients 22. Following treatment, 
milnacipran responders exhibited significantly increased pain related activation of PCC, 
associated with reduced pain sensitivity (increased P50) and lower intensities of ongoing pain, 
whereas placebo responders did not exhibit increased PCC activation, nor, as reported in the 
present sudy, reduced pain sensitivity. However, both groups had increased pain related 
activation of the amygdala following treatment. Amygdala has been associated with 
cannabinoid analgesia mediating the reduction of unpleasantness of ongoing pain, but not 
reduced pain sensitivity 33. Thus, our previous fMRI results would indicate that the placebo 
response associated with clinical improvement in our FM cohort could involve 
endocannabinoid or possibly dopaminergic mechanisms, both previously implicated in 
placebo analgesia 11, 24, rather than endogenous opioids. Hypothetically, these non-opioid 
mechanisms are less influenced by pain duration and therefore explain the presence of 
placebo responses also in FM patients with long disease duration. 
     We did not find any baseline group differences in pain sensitivity (P50) between placebo 
responders and non-responders, which tallies our previous results 22. The lack of statistically 
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significant group differences could be explained by the large inter-individual variability in 
pressure pain sensitivity, which has been reported also in healthy subjects 29. Despite the lack 
of an overall significant increase in P50 within the placebo group, patients with shorter pain 
duration had larger reductions in pain sensitivity. These results are in accordance with our 
previous findings that short pain duration was a positive predictor for milnacipran response, 
associated with significant reductions in pain sensitivity (increased P50) 22. The findings 
would indicate differential mechanisms for placebo reductions in pain sensitivity, that are 
negatively influenced by pain duration and possibly more dependent on endogenous opioids, 
and the placebo response influencing the more emotional/cognitive aspects of clinical pain. 
     To our knowledge, this is the first study addressing the impact of chronification on placebo 
responses, by assessing the relationship between FM duration and placebo analgesia. As 
mentioned, a previous study from our group demonstrated significant neural plasticity in 
relation to FM duration, including cerebral atrophy in pain inhibitory regions 23, indicating 
that time would likely be a key variable when assessing FM treatment mechanisms. The 
present results suggest that FM duration influences endogenous pain regulation, as placebo 
responses were negatively affected in the placebo arm of a randomized double-blinded 
clinical trial.  
     A partial correlation, controlling for depression and catastrophizing, confirmed that the 
relationship between FM duration and treatment outcome was not explained by differences in 
negative affect. As the primary outcome of this trial gave different results if FM duration was 
not taken into account, our results point to the importance of taking pain duration into 
consideration when interpreting results from FM clinical trials, and possibly trials in other 
chronic pain conditions too. Even if our study included patients already diagnosed with FM, 
our results indicate that clinical interventions that depend on endogenous pain regulation may 
still be harnessed, and chronification avoided, if initiated early after chronic pain onset. In 
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other words, our study has generated hypotheses around early prevention of FM, by 
illustrating a potential relationship between early FM and stronger endogenous pain 
modulation. 
     The present study represents a combination of a traditional drug trial and a mechanistic 
experimental study, where the benefit of using a highly controlled treatment protocol is 
combined with the advantage of obtaining quantitative sensory data. Moreover, all patients 
were washed out of medications, which is not feasible in most experimental studies. 
     In this study we found that placebo responders had lower ratings of depression at baseline 
compared to non-responders, and less catastrophizing thoughts (even if depression and 
catastrophizing had no impact on analyses regarding FM duration). The notion of predicting 
who will be a placebo responder has intrigued researchers and pharmaceutical companies 
since the recognition of placebo effects in medicine 40, yet, there has been no conclusive 
evidence for a typical placebo responder 26. In our study, patients with less negative affect at 
baseline were more likely to be placebo responders, perhaps because they were more likely to 
form positive expectations about the treatment. Placebo analgesia is closely related to 
expectations of pain relief and accounts for a large amount of variance in placebo responses 6, 
46
. As the contextual factors are likely to vary considerably between trials, and treatment 
expectations may vary accordingly (i.e. through differences in patient-clinician relationship) 
27, 28
, it is unlikely that baseline depression and catastrophizing will always be associated with 
placebo responses. Yet, if negative affect has a negative influence on the general perception 
of the credibility of a clinical trial, this may impact placebo outcomes. In contrast to the 
baseline predictors for placebo responses in FM reported here (depression and 
catastrophizing), our previous study revealed that predictors of the response to milnacipran (a 
serotonergic-/noradrenergic drug) was independent of psychological variables 22. 
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     An overall correlation showed that weekly pain levels were less variable over time, leading 
to more constant pain (in line with previous research suggesting that FM patients are less 
sensitive to variations in weather with time 13). Placebo responders, however, did not display 
the same transition towards more constant pain levels with longer FM duration. Hence, the 
overall relationship between less variable pain and FM duration was driven by non-
responders. It is possible that a variable pain profile is favorable for recruiting endogenous 
pain responses, as pain may still be malleable, in contrast to patients with a less flexible pain 
modulatory system. It is our hope that future pain studies will include pain variability as a 
study variable when assessing response to treatment and factors for individualizing treatment. 
 
Future studies and emerging hypotheses  
A recent meta-analysis 9 presented a statistical synthesis of 37 FM neuroimaging studies 
published before March 2015. The meta-analysis validates the idea of a dysfunction of the 
descending pain modulatory system in FM, as there was hypoactivity in the subgenual 
anterior cingulate cortex and the amygdala, together with hyperactivation of the insula. As the 
same regions are implicated in placebo analgesia, it seems reasonable that placebo responses 
decrease over time with FM pain. Yet, a small experimental study of spinal withdrawal 
reflexes in FM 14 suggests segregation between cerebral and spinal processes during 
expectancy-driven analgesia; indicating that descending pain inhibition failed to affect spinal 
activity. Thus, there is a possibility that expectancy-induced pain relief is differently 
represented in FM patients, due to constant spinal hyperexcitability. As in most other studies, 
the study on spinal reflexes did not analyse results in relation to FM duration, and patients 
were not washed out of medications (opiates, tricyclics, antiepileptic drugs etc. were taken). 
In future studies, the inclusion of pain duration in analyses of chronic pain will provide a 
better understanding of possible routes to pain relief. Recent studies have demonstrated clear 
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evidence of neural plasticity in several common pain disorders over time, including FM, and 
the search for chronic pain treatment should reflect that knowledge by taking time since pain 
onset into account. It is our hope that future studies will have a dynamic perspective on 
patien s b sed on p in du   ion,    he   h n   bin    cl ssi ie  o  “he l h ” o  “dise sed”. 
 
Limitations 
The present study used a traditional placebo-controlled design, and did not include a natural 
history control group. This means that the placebo responses could not be controlled for 
general factors such as spontaneous remission or regression to the mean. Yet, long-term 
follow up of FM patients indicate small chances of recovery 4, 12. Another limitation is the 
small sample. The present study was a secondary analysis of a RCT aimed at comparing pain 
mechanisms in response to treatment with milnacipran (n=46) and placebo (n=46). Hence the 
power in the original study was adequate, but in the present subgrouping into placebo 
responders and non-responders we have poorer power, which restricted the type of analyses 
we could perform. In a larger study, regression analyses could have provided sophisticated 
models of the contribution of different factors to placebo responses. In spite of the small 
sample size, we hope that the present study can be seen as a first indication of a new line of 
studies that take pain duration into consideration when studying the effects of treatments for 
chronic pain.  
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Figure legends 
 
Figure 1. Baseline correlation between FM duration and pain sensitivity. Correlations 
between FM duration (duration of widespread pain; months) and baseline pressure pain 
sensitivity (P50) among placebo non-responders (r(20)=-0.496, p=0.019) and placebo 
responders (r(13)=-0.318, p=0.248). 
 
Figure 2. Correlation between FM duration and P50 change. Correlations between FM 
duration (duration of widespread pain; months) and change in pressure pain sensitivity (P50) 
from baseline to after treatment among placebo non-responders (r(20)=-0.348, p=0.112) and 
placebo responders (r(13)=0.689, p=0.004). 
 
Figure 3. Baseline correlations between FM duration and pain variability. Left panel: 
Correlation between FM duration and pain variability (max-min) at baseline across placebo 
non-responders and responders (r(35)=-0.345, p=0.037). Right panel: Correlation between 
FM duration and pain variability at baseline for placebo non-responders (r(20)=-0.480, 
p=0.024)  and placebo responders (r(13)=-0.070, p=0.805). 
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Table 1. Baseline characteristics (mean ± SD). Age (years), FM duration (months), ratings 
of depression (BDI), catastrophizing (CSQ), general health (SF36), fibromyalgia impact 
(FIQ), anxiety (STAI-T) average weekly pain (VAS), pain variability (max-min average 
weekly pain), pain drawing (number of painful areas) and pressure pain sensitivity (P50).  
 
 Total  
n=37 
Non-responders 
n=22 
Responders 
n=15 
Difference 
(p-value)   
Age  45.14 ± 8.64 45.18 ± 8.75 45.07 ± 8.78 .969 
FM duration 132.15 ± 94.15 142.86 ± 102.98 115 ± 79.75 .368 
BDI  16.61 ± 9.82 19.80 ± 9.29 12.00 ± 8.91 .015* 
CSQ 14.89 ± 8.02 17.36 ± 7.22 11.27 ± 7.97 .021* 
SF36 35.95 ± 16.74 33.18 ± 15.32 40 ± 18.42 .229 
FIQ 64.40 ± 15.20 65.90 ± 11.91 62.21 ± 19.31 .447 
STAI-T 47.05 ± 10.40 49.14 ± 10.38 44.00 ± 9.97 .142 
Average weekly 
pain 
67.84 ± 14.63 68.05 ± 15.00 67.53 ± 14.58 .865 
Pain variability 44.76 ± 20.61 41.4 ± 21.40 49.67 ± 19.05 .143 
Pain drawing  8.46 ± 2.12 8.55 ± 2.08 8.33 ± 2.32 .769 
P50 395.63 ± 146.08 418.70 ± 147.15 361.80 ± 142.58 .272 
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Table 2. Change (mean ± SD) from baseline to after 12 weeks of placebo treatment. Non-
Responders=’Non-R’ and Responders=’Resp’. Fibromyalgia impact (FIQ), average weekly 
pain (VAS), pain variability (max-min average weekly pain), pain drawing (number of painful 
areas) and pressure pain sensitivity (P50). 
 Overall 
Diff 
Baseline
/after 
Non-R 
Baseline 
Non-R 
After 
Diff 
Non-R 
Baseline
/after 
Diff Non-R  
p-value 
Resp  
Baseline 
Resp 
After 
Diff Resp 
Baseline/
after 
Diff Resp  
p-value 
Non-R 
vs. Resp 
p-value 
FIQ  9.75 ± 
15.82 
65.90 ± 
11.91 
62.95 ± 
14.25 
2.94 ± 
9.47 
.160 62.21 ± 
19.31 
42.46 ± 
23.36 
19.74 ± 
18.14 
.001* .001* 
Average 
weekly pain 
(VAS) 
13.08 ± 
20.76 
67.84 ± 
14.63 
64.55 ± 
17.14 
3.50 ± 
27.13 
 67.53 ± 
14.58 
40.40 ± 
20.11 
17.93 ± 
16.44 
.001* <.001* 
Pain 
variability 
44.76 ± 
20.61 
41.4 ± 21.40 42.82 ± 
18.82 
1.40 ± 
15.40 
.570 49.67 ± 
19.05 
41.33 ± 
18.57 
8.33 ± 
23.62 
.155  .867  
Pain-
drawing 
1.16 ± 
2.77 
8.46 ± 2.12 8.64 ± 
1.46 
1.00 ± 
1.51 
.780 8.33 ± 
2.32 
5.33 ± 
3.46 
3.0 ± 
3.21 
.003* <.001* 
P50 44.45 ± 
215.31 
418.70 ± 
147.15 
462.60 ± 
220.38 
43.90 ± 
232.24 
.485 361.80 ± 
142.58 
407.10 ± 
187.8 
45.27 ± 
195.7 
.865  .841  
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HIGHLIGHTS 
 
 
• Long-term exposure to fibromyalgia was associated with lower placebo 
analgesia  
• Subjective report of placebo response correlated with clinical improvements 
• Placebo responders had lower ratings of depression symptoms at baseline 
